#Germany #Berlin #Isotopia #Isoprotrace® #DSD Pharma

Isotopia Launches Isoprotrace® in Germany

Isotopia, a prominent developer in the field of innovative radiopharmaceuticals, announced its official commercial launch of Isoprotrace® in Germany on March 10, 2025. This marks a significant development in the medical imaging landscape, particularly for prostate cancer diagnostics. The launch is accompanied by a strategic partnership with DSD Pharma, a reliable pharmaceutical distributor in Germany, which will ensure the efficient distribution of Isoprotrace® to hospitals, clinics, and diagnostic centers nationwide.

Isoprotrace®: An Innovative Approach

Isoprotrace® is a state-of-the-art radiopharmaceutical used specifically for imaging prostate cancer. The product comes as a multi-dose kit designed for the rapid preparation of a Gallium (68Ga) Gozetotide solution, intended for intravenous injection. Upon radiolabeling with Gallium chloride (68Ga), Isoprotrace® becomes indicated for Positron Emission Tomography (PET) imaging of lesions positive for Prostate-Specific Membrane Antigen (PSMA) in patients with prostate cancer under various clinical scenarios. These scenarios include the initial staging of high-risk prostate cancer patients prior to curative treatment and the suspicion of cancer recurrence based on elevated prostate-specific antigen (PSA) levels following primary curative treatment.

In Germany, prostate cancer continues to be one of the most commonly diagnosed cancers in men, with over 70,000 new cases each year. The accuracy of imaging plays a crucial role in establishing precise diagnoses and planning effective treatments.

Strategic Partnership with DSD Pharma

Tzachi Levy, the General Manager of Isotopia’s aseptic plant, expressed enthusiasm about the partnership with DSD Pharma. He stated, “We are excited to work with DSD Pharma to introduce Isoprotrace® to the German market. Germany is a key area for Isoprotrace®, and we believe that this collaboration will ensure the successful introduction and accessibility of this innovative product to healthcare providers throughout the country.”

Moreover, Susanne Dorudi, the CEO of DSD Pharma, complemented this sentiment by emphasizing the pride in this collaboration. She remarked, “This partnership allows us to provide German healthcare professionals with a revolutionary imaging solution. We are excited about the potential impact of this product and look forward to its success in the German market.”

The partnership between Isotopia and DSD Pharma also encompasses the distribution of lutetium chloride (177 Lu) n.c.a., further strengthening their portfolio of advanced solutions for cancer imaging and treatment.

Future Prospects

Isoprotrace® has already received approval in the Netherlands and is expected to be available in over ten EU countries shortly. With a reliable supply chain and proven compliance, Isotopia is committed to enhancing patient access to this innovative product while improving diagnostic accuracy and treatment outcomes for prostate cancer.

Isotopia has established itself as a leading innovator in the development of radiopharmaceutical products aimed at molecular imaging and therapy. The company's focus on providing high-quality advanced solutions reflects its commitment to improving patient care through precision medicine. Alongside DSD Pharma, Isotopia is set to make significant strides in the German healthcare market, ushering in an era of enhanced healthcare solutions for prostate cancer patients.

• ---